Pressure Overload

Heart Failure Clinics

Volumn 8, Issue 1, 2012, Pages 21-32

  Frohlich, Edward D ^a   Susic, Dinko ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Heart failure; Molecular mechanisms of myocardial hypertrophy; Ventricular dysfunction; Ventricular hypertrophy

Indexed keywords

AORTA COARCTATION; AORTA STENOSIS; CORONARY ARTERY BLOOD FLOW; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE; HEART VENTRICLE; HUMAN; HYPERTENSION; REVIEW;

CARDIOMYOPATHY, HYPERTROPHIC; DISEASE PROGRESSION; HEART FAILURE; HUMANS; VENTRICULAR DYSFUNCTION; VENTRICULAR PRESSURE; VENTRICULAR REMODELING;

EID: 82955249897     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.08.005     Document Type: Review

References (116)

1. Meerson F.Z. Compensatory hyperfunction of the heart and cardiac insufficiency. Circ Res 1962, 10:250-258.
2. Grossman W., Jones D., McLaurin I. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975, 56:50-58.
3. Frohlich E.D., Apstein C., Chobanian A., et al. The heart in hypertension. N Engl J Med 1992, 327:998-1008.
4. Barry S.P., Townsend P.A. What causes a broken heart - molecular insights into heart failure. Int Rev Cell Mol Biol 2010, 284:113-179.
5. Pfeffer J.M., Pfeffer M.A., Braunwald E. Influence of chronic captopril therapy on the infracted left ventricle of the rat. Circ Res 1985, 57:84-95.
6. Opie L.H., Commerford P.J., Gersh B.J., et al. Controversies in ventricular remodeling. Lancet 2006, 367:356-367.
7. Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure: results of 24-hour urinary sodium and potassium excretion. BMJ 1988, 297:319-328.
8. Yu H.C., Burrell L.M., Black M.J., et al. Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1999, 98:2621-2628.
9. Yuan B.X., Leenen F.H. Dietary sodium intake and left ventricular hypertrophy in normotensive rats. Am J Physiol 1991, 261:H1397-H1401.
10. Varagic J., Frohlich E.D., Díez J., et al. Myocardial fibrosis, impaired coronary hemodynamics, and biventricular dysfunction in salt- loaded SHR. Am J Physiol Heart Circ Physiol 2006, 290:H1503-H1509.
11. Varagic J., Frohlich E.D., Susic D., et al. AT1 receptor antagonism attenuates target organ effect of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol 2008, 294:H853-H858.
12. Susic D., Varagic J., Frohlich E.D. Cardiovascular effects of inhibition of renin- angiotensin-aldosterone system components in hypertensive rats given salt excess. Am J Physiol Heart Circ Physiol 2010, 298:H1177-H1181.
13. Cook N.R., Cutler J.A., Obarzanek E., et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007, 334:885-888.
14. Alpert N.R., Mulieri L.A. Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit. Circ Res 1982, 50:491-500.
15. Grove D., Zak R., Nair K.G., et al. Biochemical correlates of cardiac hypertrophy. IV. Observations on the cellular organization of growth during myocardial hypertrophy in the rat. Circ Res 1969, 25:473-485.
16. Nair K.G., Cutilletta F., Zak R., et al. Biochemical correlates of cardiac hypertrophy. I. Experimental model, changes in heart weight, RNA content and nuclear RNA polymerase activity. Circ Res 1968, 23:451-462.
17. Bruel A., Christofersen T.E., Nyengaard J.R. Growth hormone increases the proliferation of the existing cardiac myocytes and the total number of cardiac myocytes in the rat heart. Circ Res 2007, 76:400-408.
18. Leeuwenburgh B.P., Helbing W.A., Wenink A.C., et al. Chronic right ventricular pressure overload results in hyperplastic rather than hypertrophic response. J Anat 2008, 212:286-294.
19. Du Y., Plante E., Janicki J.S., et al. Temporal evaluation of cardiac myocyte hypertrophy and hyperplasia in male rats secondary to chronic volume overload. Am J Pathol 2010, 177:1155-1163.
20. Astorri E., Bolognesi R., Colla B., et al. Left ventricular hypertrophy: a cytometric study on 42 human hearts. J Mol Cell Cardiol 1977, 9:763-775.
21. Linzbach A.J. Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960, 5:370-381.
22. Kajstura J., Leri A., Finato N., et al. Myocardial proliferation in end-stage cardiac failure in humans. Proc Natl Acad Sci U S A 1998, 95:8801-8805.
23. Beltrami C.A., Urbanek K., Kajstura J., et al. Evidence that human cardiac myocytes divide after infarction. N Engl J Med 2001, 344:1750-1757.
24. Urbanek K., Quaini F., Tasca G., et al. Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy. Proc Natl Acad Sci U S A 2003, 100:10440-10445.
25. Linke A., Muller P., Nurzynska D., et al. Cardiac stem cells in the dog regenerate infarcted myocardium improving cardiac performance. Proc Natl Acad Sci U S A 2005, 102:8966-8971.
26. Anversa P., Nadal-Ginard B. Myocyte renewal and ventricular remodeling. Nature 2002, 415:240-243.
27. Anversa P., Leri A., Kajstura J. Cardiac regeneration. J Am Coll Cardiol 2006, 47:1769-1776.
28. Chien K.R. Stem cells: lost in translation. Nature 2004, 428:607-608.
29. Anversa P., Ricci R., Olivetti G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: a review. J Am Coll Cardiol 1986, 7:1140-1149.
30. Jalil J.E., Doering C.W., Janicki J.S., et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989, 64:1041-1050.
31. Camelitti P., Borg T.K., Kohl P. Structural and functional characterization of cardiac fibroblasts. Cardiovasc Res 2005, 65:40-51.
32. Diez J., Frohlich E.D. A translational approach to hypertensive heart disease. Hypertension 2010, 55:1-8.
33. Frohlich E.D., Gonzales A., Diez J. Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocyte hypertrophy. J Hypertens 2011, 29:17-26.
34. Weber K.T., Janicki J.S., Shroff S.G., et al. Collagen remodeling of the pressure overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988, 62:756-765.
35. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and the renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
36. Swynghedauw B. Phenotypic plasticity of adult myocardium: molecular mechanisms. J Exp Biol 2006, 209:2320-2327.
37. Lompre A.M., Schwartz K., D'Albis A., et al. Myosin isozymes redistribution in chronic heart loading. Nature 1979, 282:105-107.
38. Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscle. Physiol Rev 1986, 66:710-771.
39. Miyata S., Minobe W., Bristow M.R., et al. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000, 86:386-390.
40. Linke W.A. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res 2008, 77:637.
41. Zile M.R., Brutsaert D.L. New concepts in diastolic function and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 2002, 105:1503-1508.
42. Frohlich E.D. Fibrosis and ischemia: the real risk in hypertensive heart disease. Am J Hypertens 2001, 14:194s-199s.
43. Kannel W.B., Castelli W.P., McNamara P.M., et al. Role of blood pressure in the development of congestive heart failure: the Framingham study. N Engl J Med 1972, 287:781-787.
44. Dunn F.G., Pringle S.D. Left ventricular hypertrophy and myocardial ischemia in systemic hypertension. Am J Cardiol 1987, 60:191-221.
45. Yiu K.H., Tse H.F. Hypertension and cardiac arrhythmias: a review of epidemiology, pathophysiology and clinical implications. J Hum Hypertens 2008, 22:380-388.
46. Manolis A.J., Beldekos D., Handanis S., et al. Comparison of spirapril, isradipine or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. J Hypertens 2002, 11:1445-1450.
47. Tarazi R.C., Miller A., Frohlich E.D., et al. Electrocardiographic changes reflecting left atrial abnormality in hypertension. Circulation 1966, 34:818-822.
48. Dunn F.G., Pfeffer M.A., Frohlich E.D. ECG alterations with progressive left ventricular hypertrophy in spontaneous hypertension. Clin Exp Hypertens 1978, 1:67-86.
49. Ravelli F., Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997, 90:1686-1695.
50. Tanaka K., Zlochiver S., Vikstrom K.L., et al. The spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. Circ Res 2007, 101:839-847.
51. Goette A., Staack T., Rocken C., et al. Increased expression of extracellular signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000, 35:1669-1677.
52. Brasier A.R., Recinos A., Eledrisi M.S. Vascular inflammation and the renin- angiotensin system. Arterioscler Thromb Vasc Biol 2002, 22:1257-1266.
53. Frohlich E.D., Tarazi R.C., Dustan H.P. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation 1971, 44:446-455.
54. Muller-Brunotte R., Kahan T., Lopez B., et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007, 25:1958-1966.
55. Erdogan D., Yildirim I., Ciftci O., et al. Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function. Circulation 2007, 115:593-599.
56. Barron H.V., Lesh M.D. Autonomic nervous system and sudden cardiac death. J Am Coll Cardiol 1996, 27:1053-1060.
57. Harrap S.B., Mitchell G.A., Casley D.J., et al. Angiotensin II, sodium, and cardiovascular hypertrophy in spontaneously hypertensive rats. Hypertension 1993, 21:50-55.
58. Hart G. Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res 1994, 28:933-946.
59. Savelieva I., Yap Y.G., Yi G., et al. Relation of ventricular repolarization to cardiac cycle length in normal subjects, hypertrophic cardiomyopathy, and patients with myocardial infarction. Clin Cardiol 1999, 22:649-654.
60. Tribulova N., Okruhlicova L., Novakova S., et al. Hypertension-related intermyocyte junction remodeling is associated with a higher incidence of low-K(+)-induced lethal arrhythmias in isolated rat heart. Exp Physiol 2002, 87:195-205.
61. Zaugg C.E., Wu S.T., Lee R.J., et al. Intracellular Ca2+ handling and vulnerability to ventricular fibrillation in spontaneously hypertensive rats. Hypertension 1997, 30:461-467.
62. Haider A.W., Larson M.G., Benjamin E.J., et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998, 32:1454-1459.
63. Dunn F.G., Chandraratna P., de Carvalho J.G.R., et al. Pathophysiologic assessment of hypertensive heart disease with echocardiography. Am J Cardiol 1977, 39:789-795.
64. Dreslinski G.R., Frohlich E.D., Dunn F.G., et al. Echocardiographic diastolic ventricular abnormality in hypertensive heart disease: atrial emptying index. Am J Cardiol 1981, 47:1087-1090.
65. Aeschbacher B.C., Hutter D., Fuhrer J., et al. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 2001, 14:106-113.
66. Shepherd R.F., Zachariah P.K., Shub C. Hypertension and left ventricular diastolic function. Mayo Clin Proc 1989, 64:1521-1532.
67. Zile M.R., Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis and measurements of diastolic function. Circulation 2002, 105:1503-1508.
68. Brutsaert D.L. Cardiac dysfunction in heart failure: the cardiologist's love affair with time. Prog Cardiovasc Dis 2006, 49:157-181.
69. Yip G.W., Fung J.W., Tan Y.T., et al. Hypertension and heart failure: a dysfunction of systole, diastole or both. J Hum Hypertens 2009, 23:295-306.
70. Fouad F.M., Slominski J.M., Tarazi R.C. Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol 1984, 53:1387-1393.
71. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999, 79:216-262.
72. Swinghedauw B. Molecular mechanisms in evolutionary cardiology failure. Ann N Y Acad Sci 2010, 1188:58-67.
73. 2+ transport and mechanics in compensated pressure overloaded hypertrophy and heart failure. Circ Res 1995, 77:759-764.
74. Houser S.R., Piacentino V., Weisser J. Abnormalities in calcium cycling in the hypertrophied and failing heart. J Mol Cell Cardiol 2002, 32:1595-1607.
75. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989, 13:1637-1652.
76. Brower G.L., Gardner J.D., Forman M.F., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006, 30:604-610.
77. DeSimone G., DeDivitiis O. Extracellular matrix and left ventricular mechanics in overload hypertrophy. Adv Clin Path 2002, 6:3-10.
78. Re R.N. The intracellular renin-angiotensin system: the tip of intracrine physiology iceberg. Am J Physiol Heart Circ Physiol 2007, 293:H905-H906.
79. Kumar R., Singh V.P., Baker K.M. The intracellular rennin-angiotensin system: implication in cardiovascular remodeling. Curr Opin Nephrol Hypertens 2008, 17:168-173.
80. Xu J., Carretero O.A., Liao T.D., et al. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol 2010, 299:H1304-H1306.
81. Kehat I., Molkentin J.D. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010, 122:2727-2735.
82. Bache R.J. Effects of hypertrophy on the coronary circulation. Prog Cardiovasc Dis 1988, 30:403-440.
83. Marcus M.L., Harrison D.G., Chilian W.M., et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987, 75(Suppl 1):I19-I25.
84. Levy A.S., Chung J.C.S., Kroetsch J.T., et al. Nitric oxide and coronary vascular endothelium adaptations in hypertension. Vasc Health Risk Manag 2009, 5:1075-1087.
85. Susic D., Francischetti A., Frohlich E.D. Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged SHR and normal rats. Hypertension 1999, 33(1 Pt 2):451-455.
86. Mancini G.B., Dahlöf B., Díez J. Surrogate markers for cardiovascular disease. Structural markers. Circulation 2004, 109(25 Suppl 1):IV22-IV30.
87. Ruilope L.M., Schmieder R.E. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008, 21:500-508.
88. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991, 114:345-352.
89. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
90. Kahan T., Bergfeldt L. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential. Heart 2005, 91:250-256.
91. Kaplinsky E. Do we understand why regression of left ventricular hypertrophy is beneficial?. Cardiovasc Res 2003, 60:463-464.
92. Devereux R.B., Wachtell K., Gerdts E., et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004, 292:2350-2356.
93. Okin P.M., Devereux R.B., Jern S., et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004, 292:2343-2349.
94. Verma A., Solomon S.D. Diastolic dysfunction as a link between hypertension and heart failure. Med Clin North Am 2009, 93:647-664.
95. Kannel W.B. Incidence and epidemiology of heart failure. Heart Fail Rev 2000, 5:167-173.
96. Chinnaiyan K.M., Alexander D., Maddens M., et al. Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. Am Heart J 2007, 153:189-200.
97. Hamdani N., Paulus W.J. Treatment of heart failure with normal ejection fraction. Curr Treat Options Cardiovasc Med 2011, 13:26-34.
98. Gradman A.H., Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis 2006, 48:326-341.
99. Lionetti V., Recchia F.A. New therapies for the failing heart: trans-genes versus trans-cells. Transl Res 2010, 156:130-135.
100. Bolli P., Chaudhry H.W. Molecular physiology of cardiac regeneration. Ann N Y Acad Sci 2010, 1211:113-126.
101. Guyette J.P., Cohen I.S., Gauchette G.R. Strategies for regeneration of heart muscle. Crit Rev Eukaryot Gene Expr 2010, 20:2035-2050.
102. Hannenhalli S., Putt M.E., Gimore J.M., et al. Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 2006, 114:1269-1276.
103. Meijs M.F., deWindt L.J., deJonge N., et al. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 2007, 14:157-171.
104. Luedde M., Katus H.A., Frey N. Novel molecular targets in the treatment of cardiac hypertrophy. Recent Pat Cardiovasc Drug Discov 2006, 1:1-20.
105. Samuel J.L., Swynghedauw B. Is cardiac hypertrophy a required compensatory mechanism in pressure-overloaded heart. J Hypertens 2008, 26:857-858.
106. Diez J. Towards a new paradigm about hypertensive heart disease. Med Clin North Am 2009, 93:637-646.
107. Beer M., Seyfarth T., Sandestede J., et al. Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy. J Am Coll Cardiol 2002, 40:1267-1274.
108. Wende A.R., Abel E.D. Lipotoxicity in the heart. Biochim Biophys Acta 2010, 1801:311-319.
109. Gonzales A., Lopez B., Ravassa S., et al. Stimulation of apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002, 39:75-80.
110. Rothermal B.A., Hill J.A. Autophagy in load-induced heart disease. Circ Res 2008, 103:1363-1369.
111. Berk B.C., Fujiwara K., Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007, 117:568-575.
112. McLenachan J.M., Dargie J.H. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relation to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens 1990, 3:735-740.
113. Feihl F., Liaudet L., Waeber B. The macrocirculation and microcirculation of hypertension. Curr Hypertens Rep 2009, 11:182-189.
114. Susic D., Nunez E., Hosoya K., et al. Coronary hemodynamics in aging spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY) rats. J Hypertens 1998, 16:231-237.
115. Isoyama S., Ito N., Satoh K., et al. Collagen deposition and the reversal of coronary reserve in cardiac hypertrophy. Hypertension 1992, 20:491-500.
116. Lapu-Bula R., Ofili E. From hypertension to heart failure: role of nitric oxide- mediated endothelial dysfunction and emerging insights from myocardial contrast echocardiography. Am J Cardiol 2007, 99:7D-14D.